Table 2.

Treatment-related adverse events (TRAEs)

n (%)	APG-1387 monotherapy trial (n = 28)		APG-1387 combination trial (n = 22)
	All grade	Grade ≥3	All grade	Grade ≥3
Any TRAE	6 (21·4)	1 (3·6)	17 (77·3)	3 (13·6)
Headache	0 (0)	0 (0)	1 (4·5)	0 (0)
Hypogeusia	0 (0)	0 (0)	2 (9·1)	0 (0)
Facial-nerve disorder	3 (10·7)	0 (0)	0 (0)	0 (0)
Alanine aminotransferase elevation	2 (7·1)	1 (3·6)	2 (9·1)	0 (0)
Aspartate aminotransferase elevation	2 (7·1)	0 (0)	1 (4·5)	0 (0)
Asthenia	1 (3·6)	0 (0)	0 (0)	0 (0)
Pruritus	1 (3·6)	0 (0)	1 (4·5)	0 (0)
Lipase elevation	0 (0)	0 (0)	8 (36·4)	2 (9·1)
Platelet count decrease	0 (0)	0 (0)	1 (4·5)	1 (4·5)
Immune-mediated pancreatitis	0 (0)	0 (0)	1 (4·5)	1 (4·5)
Rash	0 (0)	0 (0)	6 (27·3)	0 (0)
Hypoesthesia	0 (0)	0 (0)	2 (9·1)	0 (0)
Amylase elevation	0 (0)	0 (0)	4 (18·2)	0 (0)
Blood creatinine elevation	0 (0)	0 (0)	2 (9·1)	0 (0)
Leukopenia	0 (0)	0 (0)	2 (9·1)	0 (0)
Infusion site reaction	0 (0)	0 (0)	2 (9·1)	0 (0)
Hypothyroidism	0 (0)	0 (0)	2 (9·1)	0 (0)
Decreased appetite	0 (0)	0 (0)	2 (9·1)	0 (0)

Data are presented as number (percentage) of patients.